Related Experiment Video

Updated: Jun 3, 2025

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

6.5K

Histone Deacetylase (HDAC) Inhibitors as a Novel Therapeutic Option Against Fibrotic and Inflammatory Diseases

Maria A Theodoropoulou1,2, Christiana Mantzourani1,2, George Kokotos1,2

  • 1Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.

Biomolecules
|January 8, 2025
PubMed

Insights

Histone deacetylase inhibitors (HDACis) show promise beyond cancer treatment. Research from 2020-2024 highlights their potential as anti-fibrotic and anti-inflammatory agents for various diseases.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Molecular Biology

Background:

  • Histone deacetylases (HDACs) are crucial in cancer development.
  • HDAC inhibitors (HDACis) are FDA-approved cancer treatments.
  • Emerging research links HDACs to fibrotic, inflammatory, neurodegenerative, and autoimmune diseases.

Purpose of the Study:

  • To review the development and application of HDAC inhibitors as anti-fibrotic and anti-inflammatory agents.
  • To cover research published between 2020 and 2024.
  • To explore the therapeutic potential of HDAC inhibitors beyond oncology.

Main Methods:

  • Literature review of scientific articles published from 2020-2024.
  • Analysis of research on HDAC inhibitors' roles in fibrotic and inflammatory conditions.
  • Synthesis of findings on HDAC isozyme-specific inhibition.

Main Results:

  • HDAC inhibitors are being investigated for non-cancerous diseases, including Duchenne muscular dystrophy.
  • Givinostat, an HDAC inhibitor, received FDA approval for Duchenne muscular dystrophy.
  • HDACis demonstrate potential as anti-fibrotic and anti-inflammatory therapeutics.

Conclusions:

  • HDAC inhibitors offer a promising therapeutic avenue for fibrotic, inflammatory, and other diseases.
  • Targeting specific HDAC isozymes may elucidate disease mechanisms and lead to novel treatments.
  • Continued research into HDAC inhibitors is vital for expanding their clinical applications beyond cancer.
Keywords:
HDAC inhibitorsHDACsfibrosisidiopathic pulmonary fibrosisinflammation

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

8.5K
Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue09:43

Purification of H3 and H4 Histone Proteins and the Quantification of Acetylated Histone Marks in Cells and Brain Tissue

Published on: November 30, 2018

21.2K

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
241
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
236
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
217
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141